NASDAQ : CRVO
CervoMed Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.75 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 26.46M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 24.19M |
| Enterprise Value | -747,618 |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 15.12M |
| Shares Outstanding | 15.12M |
| Shares Change (YoY) | +8.40% |
| Shares Change (QoQ) | +10.65% |
| Owned by Insiders (%) | 25.94% |
| Owned by Institutions (%) | 11.63% |
| Float | 9.60M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 73.02 |
| Forward PS | 42.19 |
| PB Ratio | 0.94 |
| P/TBV Ratio | 1.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 8.57 |
| Quick Ratio | 8.22 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -107.62% |
| Return on Assets (ROA) | -60.80% |
| Return on Invested Capital (ROIC) | -69.07% |
| Return on Capital Employed (ROCE) | -135.73% |
| Weighted Average Cost of Capital (WACC) | -19.38% |
| Revenue Per Employee | $22,086 |
| Profits Per Employee | -$2.02M |
| Employee Count | 15 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -4.30 |
| 52-Week Price Change | -76.74% |
| 50-Day Moving Average | 2.55 |
| 200-Day Moving Average | 3.51 |
| Relative Strength Index (RSI) | 24.06 |
| Average Volume (20 Days) | 350,208 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.21M |
| Short Previous Month | 1.34M |
| Short % of Shares Out | 7.99% |
| Short % of Float | 12.58% |
| Short Ratio (days to cover) | 4.11 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 331,295 |
| Gross Profit | -21.00M |
| Operating Income | -31.16M |
| Pretax Income | -30.35M |
| Net Income | -30.35M |
| EBITDA | n/a |
| EBIT | -31.16M |
| Loss Per Share | -$3.19 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 24.94M |
| Total Debt | n/a |
| Net Cash | 24.94M |
| Net Cash Per Share | $1.65 |
| Equity (Book Value) | 22.96M |
| Book Value Per Share | 1.70 |
| Working Capital | 22.96M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -27.98M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -27.98M |
| FCF Per Share | -$1.85 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -9,406.96% |
| Pretax Margin | -9,160.94% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -8.40% |
| Shareholder Yield | -8.40% |
| Earnings Yield | -199.56% |
| FCF Yield | -115.66% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $15.00 |
| Price Target Difference | 837.50% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2.74 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |